SUPPORTING INFORMATION

Indo-1 derivatives for local calcium sensing

Michael Bannwarth^{\dagger, \neq}, Ivan R. Corrêa Jr^{\dagger, \neq}, Cindy Fellay^{\dagger}, Annina Aebischer^{\dagger}, Monika Sztretye^{\ddagger}, Sandrine Pouvreau^{$\ddagger, \$}$ </sup>, Leandro Royer^{\ddagger}, Eduardo Ríos^{$\ddagger, *$}, Kai Johnsson^{$\dagger, *$}

Institute of Chemical Sciences and Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015, Lausanne, Switzerland and Section of Cellular Signaling, Department of Molecular Biophysics and Physiology, Rush University, 1750 West Harrison Street, Suite 1279JS, Chicago, IL 60612, USA

[†]: EPFL, [‡]: Rush University

[§] Present address: Physiologie Intégrative Cellulaire et Moléculaire, Université Claude Bernard Lyon 1, Villeurbanne Cedex, France.

^{*≠*}: These authors contributed equally to this work.

* Corresponding authors: erios@rush.edu; kai.johnsson@epfl.ch

Bannwarth et al.


ORGANIC SYNTHESIS

General Procedures. Chemicals were purchased from Sigma, Fluka, Aldrich, Acros or Invitrogen. Reverse phase preparative HPLC (RP-HPLC) was performed on a SunFire[™] PrepC₁₈OBD[™] 5 µm (19 x 150 mm) column using a Waters 2777C Sample Manager, Waters 600E Controller, and Waters Fraction Collector III system. For RP-HPLC separations, a linear gradient of H₂O (0.1% TFA)/MeCN (0.08% TFA) 95/5 to 0/100 and flow rate of 10 mL/min were used. Detection was achieved by a Waters 2487 Dual λ Absorbance Detector (280 nm and 350 nm). ¹H-NMR spectra were recorded on a Bruker ARX-400 (400 MHz) spectrometer at 298 K. Chemical shifts are reported on the δ scale in ppm from deuterated solvents, and referenced to solvent peaks (CDCl₃: 7.26 ppm, CD₃OD: 3.31 ppm, CD₃CN: 1.94 ppm, and D₂O: 4.79 ppm) as internal standards. Data are reported as follows: chemical shift, multiplicity (s = singlet, br = broad singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, p = quintet, and m =multiplet), integration, and coupling constants (J values, measured in Hz). ¹H-decoupled ¹³C-NMR spectra were recorded on a Bruker ARX-400 spectrometer at 298 K. Chemical shifts are reported on the δ scale in ppm from deuterated solvents, and referenced to solvent peaks (CDCl₃: 77.0 ppm, CD₃OD: 49.0 ppm, and CD₃CN: 1.32 ppm) as internal standards. Data are reported as follows: chemical shift and integration (if not equal to one). Mass spectra were recorded by electrospray ionization on a Micromass (Waters) ESI QqTof Ultima API spectrometer. UV spectra were measured on a Perkin Elmer Lambda10 UV/VIS spectrometer.

BG-NH₂ (**2**), BG-PEG₄-NH₂ (**5**) and 5-[6-(carboxy)indol-2-yl]-5'-methyl-BAPTA ethyl ester (**1**) were prepared using published procedures (*1-3*).


5-[6-(N-(4-methyl-BG)carboxyamide)indol-2-yl]-5'-methyl-BAPTA ethyl ester (3). (BG =

O-6-benzylguanine; BAPTA = 1,2-bis(2aminophenoxy)ethane-N,N,N',N'-tetraacetic acid).



EDC (8.2 mg, 42.8 µmol), HOBt (5.8 mg, 42.9 µmol) and *O*-6-(4-aminomethylbenzyl)guanine (**2**) (5.2 mg, 19.2 µmol) were added to a solution of 5-[6-(carboxy)indol-2-yl]-5'methyl-BAPTA ethyl ester (**1**) (*3*) (10.0 mg, 13.1 µmol) in DMF (0.5 mL). The mixture was stirred overnight at room temperature. The crude product was purified by reversed-phase HPLC on a C18-column using a linear gradient of acetonitrile in water containing 0.1% trifluoroacetic acid and concentrated by lyophilization to yield 9.3 mg (9.2 µmol, 70%) of BG1-Indo-1 ethyl ester (**3**). ¹H NMR (400 MHz, CD₃OD) δ 7.96 (s, 1H), 7.80 (s, 1H), 7.52 (s, 2H), 7.43 (d, *J* = 8.1, 2H), 7.38 – 7.28 (m, 4H), 6.79 (d, *J* = 8.4, 1H), 6.74 (s, 1H), 6.71 – 6.61 (m, 3H), 5.47 (s, 2H), 4.58 (s, 2H), 4.25 (s, 2H), 4.15 (s, 6H), 4.06 (s, 4H), 4.02 – 3.93 (m, 8H), 2.22 (s, 3H), 1.11 – 1.02 (m, 12H). ¹³C NMR (101 MHz, CD₃OD) δ 173.6 (2C), 173.4 (2C), 171.5, 161.7, 151.7(2C), 142.6, 140.6, 140.5, 138.1, 138.0, 136.7, 133.6, 133.2, 129.7 (2C), 128.6 (2C), 128.0, 127.1, 122.5, 120.6, 119.8, 119.6, 119.5 (2C), 114.9, 112.1, 111.2, 99.2, 68.8, 68.7, 68.3, 62.2 (2C), 62.0 (2C), 54.8 (4C), 44.4, 21.1, 14.4 (4C). HRMS-ESI (*m*/*z*): [M + Na]⁺ calcd for C₅₃H₅₉N₉O₁₂Na, 1036.4181; found, 1036.4188.


BG1-Indo-1 (4).



1 M KOH in an aqueous solution (50 μL, 50 μmol) was added to a solution of (**3**) (7.8 mg, 7.7 μmol) in THF (0.5 mL). The mixture was stirred overnight at room temperature. The product precipitated during the reaction. The solvent was carefully removed using a Pasteur pipette, and the solid was washed twice with THF. The product was dried under reduced pressure and then dissolved in 10 mM MOPS buffer solution (pH 7.2). The concentration of (**4**) was estimated to be 1.49 mM by the absorption at λ = 354 nm using the extinction coefficient of commercial Indo-1 pentapotassium salt (ε_{346} = 33000 M⁻¹cm⁻¹ at pH 7.2)(*4*). ¹H NMR (400 MHz, D₂O) δ 7.77 (s, 1H), 7.65 (s, 1H), 7.48 (d, J = 8.0, 1H), 7.36 (d, J = 8.0, 1H), 7.24 – 7.14 (m, 6H), 6.79 (br, 2H), 6.75 (d, J = 8.1, 1H), 6.69 (d, J = 7.9, 1H), 6.57 (s, 1H), 5.04 (s, 2H), 4.38 (s, 2H), 4.17 (s, 4H), 3.80 (s, 4H), 3.70 (s, 4H), 2.19 (s, 3H). ¹³C NMR (101 MHz, D₂O-CD₃OD) δ 180.2 (2C), 180.0 (2C), 171.2, 160.4, 159.9, 150.5, 150.2, 142.3, 141.7, 139.2, 138.6, 137.0, 136.0, 133.1, 132.9, 128.8 (2C), 128.4 (2C), 126.7, 125.0, 122.7, 120.8, 120.1, 119.4, 118.8, 118.6, 115.2, 112.1, 111.6, 98.5, 68.9, 68.6, 67.6, 58.2 (2C), 57.9 (2C), 44.2, 20.9. HRMS-ESI (*m/z*): [M]⁺ calcd for C₄5H₃₉N₉O₁₂K₄, 1053.1266; found, 1053.1263.

4


BG2-Indo-1 ethyl ester (6).



EDC (26.2 mg, 136.7 µmol), HOBt (18.5 mg, 136.9 µmol), and BG-PEG₄-NH₂ (**5**) (22.6 mg, 44.9 µmol) were added to a solution of 5-[6-(carboxy)indol-2-yl]-5'-methyl-BAPTA ethyl ester (**1**)^{Error! Bookmark not defined.} (33.0 mg, 43.3 µmol) in DMF (2.0 mL). The mixture was stirred overnight at room temperature. The crude product was purified by reversed-phase HPLC on a C18-column using a linear gradient of acetonitrile in water containing 0.1% trifluoroacetic acid and concentrated by lyophilization to yield 18.6 mg (14.9 µmol, 71%) of (**6**). ¹H NMR (400 MHz, CD₃CN) δ 7.89 (s, 1H), 7.79 (s, 1H), 7.74 (m, 2H, CONH), 7.69 (s, 1H), 7.51 (d, *J* = 8.4, 1H), 7.49 (s, 1H), 7.46 – 7.41 (m, 2H), 7.22 (d, *J* = 8.0, 2H), 7.11 (d, *J* = 8.3, 1H), 7.06 (d, *J* = 7.9, 2H), 6.96 (d, *J* = 8.1, 1H), 6.84 (s, 1H), 6.83 (s, 1H), 6.75 (d, *J* = 8.0, 1H), 5.61 (s, 2H, NH₂), 5.32 (s, 2H), 4.34 (br, 2H), 4.26 (d, *J* = 5.9, 2H), 4.23 (br, 2H), 4.14 (s, 2H), 4.07 – 3.97 (m, 6H), 3.97 – 3.90 (m, 8H), 3.83 (s, 4H), 3.70 – 3.66 (m, 2H), 3.65 – 3.61 (m, 2H), 3.58 – 3.55 (m, 2H), 1.04 (t, *J* = 7.1, 6H). ¹³C NMR (101 MHz, CD₃CN) δ 174.1 (2C), 174.0 (2C), 172.0, 170.3,

161.1, 151.9, 151.5, 141.4, 139.6, 139.1, 137.8, 136.6, 136.4, 135.8, 132.6, 129.7 (2C), 129.2,
128.4, 128.2 (2C), 122.6, 120.5, 120.0, 119.7, 119.6, 119.5, 113.7, 112.2, 110.1, 99.7, 72.5, 71.0,
70.5 (2C), 70.1, 70.0 (2C), 69.9, 68.2, 67.4, 66.9, 62.7 (2C), 62.6 (2C), 56.0 (2C), 55.9 (2C),
43.2, 40.1, 21.1, 14.4 (2C), 14.3 (2C). HRMS-ESI (*m/z*): [M + Na]⁺ calcd for C₆₃H₇₈N₁₀O₁₇Na,
1269.5444; found, 1269.5455.


BG2-Indo-1 (7).



1 M KOH in an aqueous solution (45 µL, 45 µmol) was added to a solution of (6) (9.0 mg, 7.2 µmol) in THF (0.5 mL). The mixture was stirred overnight at room temperature. The product precipitated during the reaction. The solvent was carefully removed using a Pasteur pipette, and the solid was washed twice with THF. The product was dried under reduced pressure and then dissolved in 10 mM MOPS buffer solution (pH 7.2). The concentration of (7) was estimated to be 1.78 mM by the absorption at λ = 356 nm using the extinction coefficient of commercial Indo-1 pentapotassium salt (ϵ_{346} = 33000 M⁻¹cm⁻¹ at pH 7.2) (4). ¹H NMR (400 MHz, D₂O) δ 7.80 (s, 1H), 7.69 (s, 1H), 7.47 (d, *J* = 8.2, 1H), 7.36 (d, *J* = 7.9, 3H), 7.30 (s, 1H), 7.22 (d, *J* = 8.2, 1H),

7.17 (d, J = 7.8, 2H), 6.87 (s, 2H), 6.82 (d, J = 8.4, 1H), 6.80 – 6.71 (m, 2H), 6.54 (s, 1H), 5.26 (s, 2H), 4.29 (br, 2H), 4.28 (br, 2H), 4.23 (s, 2H), 3.84 (br, 6H), 3.73 (br, 4H), 3.57 (t, J = 4.5, 2H), 3.49 (br, 4H), 3.42 (d, J = 2.8, 2H), 3.39 (s, 4H), 3.33 – 3.31 (m, 4H), 2.21 (s, 3H). ¹³C NMR (101 MHz, D₂O-CD₃OD) δ 180.0 (2C), 179.9 (2C), 173.2, 172.2, 160.4, 158.91, 150.8, 150.4, 142.5, 141.9, 138.7, 138.3, 137.2, 136.9, 133.4, 133.0, 129.0 (2C), 128.4 (2C), 126.9, 125.4, 122.6, 120.8, 120.2, 119.4, 118.9, 118.9, 115.0, 112.4, 111.6, 98.7, 71.3, 70.6, 70.5 (3C), 70.4 (2C), 69.9, 68.8, 68.7, 67.5, 58.3 (2C), 58.0 (2C), 43.2, 40.6, 21.0. [M+H]⁺ calcd for C₅₅H₆₃N₁₀O₁₇, 1135.437; found, 1135.467.


5-[6-(*N*-(3-azidopropan-1-yl)carboxyamide)indol-2-yl]-5'-methyl-BAPTA ethyl ester (8). (BAPTA = 1,2-bis(2aminophenoxy)ethane-N,N,N',N'-tetraacetic acid).



EDC (78.0 mg, 406.9 μ mol), HOBt (53.7 mg, 397.4 μ mol), and 3-azido-1-propanamine (39.5 mg, 394.5 μ mol) were added to a solution of 5-[6-(carboxy)indol-2-yl]-5'-methyl-BAPTA ethyl ester (1) (103.3 mg, 135.6 μ mol) in DMF (4.0 mL). The mixture was stirred for 1 h at room temperature. The crude product was purified by reversed-phase HPLC on a C18-column using a linear gradient of acetonitrile in water containing 0.1% trifluoroacetic acid and concentrated by

lyophilization to yield 91.5 mg (108.4 μ mol, 80%) of (8). ¹H NMR (400 MHz, CDCl₃) δ 9.99 (s, 1H), 7.99 (s, 1H), 7.57 (d, *J* = 8.3, 1H), 7.49 (d, *J* = 8.3, 1H), 7.17 (d, *J* = 8.3, 1H), 7.12 (s, 1H), 6.97 (t, *J* = 5.3, 1H), 6.80 – 6.71 (m, 2H), 6.67 (d, *J* = 6.4, 1H), 6.66 (s, 1H), 6.56 (s, 1H), 4.14 (s, 4H), 4.11 (s, 4H), 4.10 – 4.01 (m, 12H), 3.96 (s, 2H), 3.49 (dt, *J* = 6.3, 12.3, 2H), 3.40 (t, *J* = 6.5, 2H), 2.24 (s, 3H), 1.88 (p, *J* = 6.6, 2H), 1.18 (t, *J* = 7.1, 6H), 1.12 (t, *J* = 7.1, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 171.8 (2C), 171.4(2C), 169.5, 150.2 (2C), 141.1, 139.2, 136.4 (2C), 132.3, 132.0, 126.4, 125.8, 121.7, 119.8, 119.0, 118.8, 118.4, 118.2, 114.1, 111.2, 111.0, 98.4, 67.3, 66.7, 61.0 (2C), 60.9 (2C), 53.7 (4C), 49.4, 37.8, 28.7, 20.8, 14.0 (2C), 13.9 (2C). HRMS-ESI (*m/z*): [M + H]⁺ calcd for C₄₃H₅₄N₇O₁₁, 844.3881; found, 844.3889.


BG3-Indo-1 ethyl ester (13).



Indo-1 azido ethyl ester (8) (33.8 mg, 40.1 μ mol) and BG alkyne (2)(18.2 mg, 51.9 μ mol) were solubilized in DCM/*i*PrOH (1:1) (2.0 mL). Water (0.5 mL), an aqueous solution of 1 M CuSO₄ (40 μ L, 40 μ mol) and an aqueous solution of 2 M sodium (40 μ L, 80 μ mol) were added to this solution. The mixture was stirred for 24 h at 60°C. After this period, the suspension was centrifuged to remove the solid particles. The crude product in the supernatant was purified by

reversed-phase HPLC on a C18-column using a linear gradient of acetonitrile in water containing 0.1% trifluoroacetic acid and concentrated by lyophilization to yield 15.3 mg (12.8 μ mol, 32%) of (**13**). ¹H NMR (400 MHz, CDCl₃) δ 10.30 (s, 1H, N_{ind}H), 7.88 (s, 2H), 7.73 – 7.62 (m, 3H), 7.40 – 7.28 (m, 2H), 7.20 – 7.02 (m, 5H), 6.96 (s, 1H), 6.95 (s, 1H), 6.87 (d, *J* = 7.7, 1H), 6.74 (s, 1H), 6.69 (d, *J* = 8.0, 1H), 6.65 (s, 1H), 6.53 (s, 1H), 5.11 (s, 2H), 4.36 (br, 2H), 4.18 – 4.09 (m, 12H), 4.09 – 3.92 (m, 10H), 3.30 (br, 2H), 2.96 (br, 2H), 2.60 (br, 2H), 2.23 (s, 3H), 2.12 (br, 2H), 1.18 – 1.05 (m, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 172.8, 171.6 (2C), 171.0 (2C), 170.6, 159.6, 155.2, 150.2 (2C), 150.0, 144.0, 141.0, 138.8, 138.6, 136.2, 134.6, 134.3, 132.9, 132.1, 128.7 (2C), 127.3 (2C), 125.4 (2C), 121.8, 120.0, 119.8, 118.7 (2C), 116.9, 114.0, 113.9, 111.2, 110.0, 98.2, 67.1, 66.9, 66.8, 61.3 (2C), 61.2 (2C), 54.2 (2C), 53.7 (2C), 49.9, 43.2, 39.5, 37.0, 33.9, 29.0, 20.9, 13.9 (2C), 13.8 (2C). HRMS-ESI (*m*/*z*): [M + H]⁺ calcd for C₆₁H₇₂N₁₃O₁₃, 1194.5372; found, 1194.5430.

BG3-Indo-1 (10).




An aqueous solution of 1 M KOH (100 μ L, 100 μ mol) was added to a solution of (**13**) (12.5 mg, 10.5 μ mol) in THF (0.5 mL). The mixture was stirred overnight at room temperature. The solvent was removed under reduced pressure. The crude product was solubilized in water and

purified by reversed-phase HPLC on a C18-column using a linear gradient of acetonitrile in water containing 0.1% trifluoroacetic acid. Before lyophilization, the product fractions from HPLC were basified to pH 8-9 using 0.1 M KOH aqueous, since degradation was observed at some extension when the product was directly concentrated from TFA solutions. The product BG3-Indo-1 (**10**) was dissolved in 10 mM MOPS buffer solution (pH 7.2), and the final concentration was estimated to be 1.03 mM by the absorption at λ = 358 nm via the extinction coefficient of commercial Indo-1 pentapotassium salt (ε_{346} = 33000 M⁻¹cm⁻¹ at pH 7.2) (*4*). ¹H NMR (400 MHz, D₂O) δ 7.66 (s, 1H), 7.53 (s, 1H), 7.53 (s, 1H), 7.45 (d, *J* = 8.2, 1H), 7.31 (d, *J* = 8.5, 1H), 7.17 (d, *J* = 7.8, 2H), 7.07 (d, *J* = 8.1, 1H), 7.00 – 6.91 (m, 3H), 6.86 – 6.78 (m, 2H), 4.03 (s, 4H), 3.72 (s, 4H), 3.65 (s, 4H), 3.20 (t, *J* = 5.3, 2H), 2.90 (t, *J* = 6.4, 2H), 2.46 – 2.38 (m, 2H), 2.22 (s, 3H), 2.07 – 2.01 (m, 2H). MS-ESI (*m*/*z*): [M+H]⁺ calcd for C₅₃H₅₆N₁₃O₁₃, 1082.41; found, 1082.46.

5-[6-(N-(3-azidopropan-1-yl)carboxyamide)indol-2-yl]-5'-methyl-BAPTA


(acetyloxy)methyl ester (11). (BAPTA = 1,2-bis(2aminophenoxy)ethane-N,N,N',N'-tetraacetic acid).



An aqueous solution of 1 M KOH (600 µL, 600 µmol) was added to a solution of (8) (49.6 mg, 58.8 µmol) in THF/MeOH (4:1) (2.0 mL). The mixture was stirred overnight at room temperature. After this period, 1M HCl aqueous solution (750 µL, 750 µmol) was added to the reaction mixture, which was then portioned between water and ethyl acetate. The organic phase was separated, washed with brine, dried over anhydrous MgSO₄, and concentrated. The crude product was dissolved in DMF (2.0 mL) and cooled to 0°C. DIPEA (100 µL, 0.61 mmol) and bromomethyl acetate (120 µL, 1.22 mmol) were added to this solution. The mixture was stirred for 2 h at 0°C. The crude product was purified by reversed-phase HPLC on a C18-column using a linear gradient of acetonitrile in water containing 0.1% trifluoroacetic acid and concentrated by lyophilization to yield 26.6 mg (26.1 µmol, 44%) of (11). ¹H NMR (400 MHz, CDCl₃) δ 9.80 (s, 1H), 7.96 (s, 1H), 7.55 (d, J = 8.3, 1H), 7.42 (d, J = 7.4, 1H), 7.29 – 7.23 (m, 2H), 6.85 (d, J = 8.6, 1H), 6.77 (d, J = 8.0, 1H), 6.72 – 6.65 (m, 4H), 5.63 (s, 4H), 4.30 (s, 2H), 4.21 (s, 6H), 4.15 (s, 4H), 3.53 (q, J = 6.4, 2H), 3.40 (t, J = 6.6, 2H), 2.24 (s, 3H), 2.06 (s, 6H), 2.02 (s, 6H), 1.89 (p, J = 6.6, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 170.3 (2C), 169.9 (2C), 169.7 (2C),

169.5 (2C), 168.7, 150.5, 150.4, 140.7, 138.7, 136.5, 135.9, 133.0, 131.8, 127.2, 126.6, 122.0, 119.8 (2C), 119.5, 119.3, 118.0, 114.6, 111.3, 111.0, 98.8, 79.3 (2C), 79.2 (2C), 67.5, 67.0, 53.5 (2C), 53.3 (2C), 49.4, 37.7, 28.8, 20.9, 20.6 (4C). HRMS-ESI (m/z): $[M + H]^+$ calcd for C₄₇H₅₄N₇O₁₉, 1020.3474; found, 1020.3447.

AM-BG3-Indo-1 (12).



Indo-1 azido AM ester (**11**) (15.5 mg, 15.2 µmol) and BG alkyne (**9**) (8.1 mg, 23.1 µmol) were solubilized in DCM/*i*PrOH (1:1) (2.0 mL). Water (0.5 mL), an aqueous solution of 1 M CuSO₄ (25 µL, 25 µmol) and an aqueous solution of 2 M sodium ascorbate (25 µL, 50 µmol) were added to this solution. The mixture was stirred for 48 h at room temperature. After this period, the suspension was centrifuged to remove the solid particles. The crude product in the supernatant was purified by reversed-phase HPLC on a C18-column using a linear gradient of acetonitrile in water containing 0.1% trifluoroacetic acid and concentrated by lyophilization to yield 15.2 mg (11.1 µmol, 73%) of AM-BG3-Indo-1 ester (**12**). The concentration of AM-BG3-Indo-1 (**12**) was estimated to be 2.03 mM after 1 M KOH aqueous hydrolysis to BG3-Indo-1 ester (**10**). The absorption at λ = 358 nm was measured as described before. ¹H NMR (400 MHz, CD₃OD) δ 7.88 (s, 1H), 7.70 (s, 1H), 7.51 (d, *J* = 8.3, 1H), 7.46 – 7.32 (m, 6H), 7.16 (d, *J* = 7.9,

2H), 6.89 (d, J = 8.3, 1H), 6.82 (s, 1H), 6.79 – 6.73 (m, 2H), 6.68 (d, J = 7.6, 1H), 5.61 (s, 4H), 5.58 (s, 4H), 5.45 (s, 2H), 4.42 (br, 4H), 4.31 (br, 4H), 4.24 (s, 4H), 4.14 (s, 4H), 3.40 (t, J = 6.5, 2H), 2.98 (t, J = 7.2, 2H), 2.54 (t, J = 7.2, 2H), 2.26 (s, 3H), 2.23 – 2.13 (m, 2H), 2.02 (s, 6H), 1.97 (s, 6H). MS-ESI (m/z): [M + H]⁺ calcd for C₆₅H₇₂N₁₃O₂₁, 1370.5; found, 1370.4.




Figure S1: Absorption spectra of different Indo-1 derivatives and their conjugates with SNAP-tag; conditions see Materials and Methods.





Figure S2: Determination of the K_D values of the different Indo-1 derviatives by plotting of $\log \frac{R-R_{\min}}{R_{\max}-R} \cdot \frac{F_{free anion,485 nm}}{F_{Ca^{2+}complex,485 nm}}$ against log [Ca²⁺]_{free} (in nM) according to (5). A: Indo-1; B: SNAP + Indo-1;


C: BG1-Indo-1; **D**: SNAP-1-Indo-1; **E**: BG2-Indo-1; **F**: SNAP-2-Indo-1; **G**: BG3-Indo-1; **H**: SNAP-3-Indo-1. Plots were obtained using the computer program OriginPro (OriginLab) using the fitting function y=a*(x-b)

with
$$y = \log \frac{R - R_{\min}}{R_{\max} - R} \cdot \frac{F_{free anion,485 nm}}{F_{Ca^{2+}complex,485 nm}}$$
, $x = \log [Ca^{2+}_{free}]$ and $K_D^{app} = 10^b$. Errors in


 $\log \frac{R - R_{\min}}{R_{\max} - R} \cdot \frac{F_{free anion, 485 nm}}{F_{Ca^{2*} complex, 485 nm}}$ were estimated by consideration of the error propagation of the uncertainties

in the measured fluorescence values. As weighting constraint in the program the instrumental option was chosen. Errors in K_D were obtained from the error value obtained for b by the program. Specifically, the errors given in Table 1 were calculated with the formula $10^{b+2 \cdot (error \ of \ b)} - 10^{b}$ using the uncertainty of b obtained by the fitting program.






Chi^2/I	DoF = 1.4	13906; R^2 = 0.93394
а	0.94909	0.07953
b	2.75288	0.05559



Chi	^2/DoF =	0.64435; R^2 = 0.96141
а	1.11516	0.1052
b	2.54023	0.04912



Chi	^2/DoF =	0.13835; R^2 = 0.98737
а	1.17133	0.13461
b	2.46499	0.05307

REFERENCES

- 1. Keppler, A., Gendreizig, S., Gronemeyer, T., Pick, H., Vogel, H., and Johnsson, K. (2003) A general method for the covalent labeling of fusion proteins with small molecules in vivo, *Nat Biotechnol 21*, 86-89.
- 2. Banala, S., Arnold, A., and Johnsson, K. (2008) Caged substrates for protein labeling and immobilization, *Chembiochem* 9, 38-41.
- 3. Sanchez-Martin, R. M., Cuttle, M., Mittoo, S., and Bradley, M. (2006) Microspherebased real-time calcium sensing, *Angewandte Chemie (International ed 45*, 5472-5474.
- 4. Haugland, R. P. (2002) *Handbook of Fluorescent Probes and Research Products;* Ninth Ed.
- 5. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties, *The Journal of Biological Chemistry 260*, 3440-3450.